Idorsia Ltd. announced that QUVIVIQ™ (daridorexant) is now available to patients in Switzerland for the treatment of adult patients with chronic insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning. Chronic insomnia is one of the most prevalent sleep disorders in Switzerland, affecting 9.2% of the working-age population, and impacts both physical and mental health.According to a recent report from the RAND Corporation,more than CHF 10 billion is lost from annual GDP in Switzerland due to reduced productivity associated with chronic insomnia. QUVIVIQ is the first dual orexin receptor antagonist (DORA) available in Switzerland for the treatment of chronic insomnia disorder.

Rather than inducing sleep through broad inhibition of brain activity (sedation), QUVIVIQ blocks the activation of orexin receptors known for their key role in wakefulness. Consequently, QUVIVIQ decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages. The recommended dose of QUVIVIQ is one tablet of 50 mg once per night, taken orally in the evening within 30 minutes before going to bed.

In certain circumstances, such as patients with moderate hepatic impairment or who are taking moderate CYP3A4 inhibitors, the recommended dose is 25 mg once per night.